Log in to your Inderes Free account to see all free content on this page.
Cinclus Pharma
33.5 SEK 0%Be the first to follow this company
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CINPHA
Daily low / high price
32.9 / 33.5
SEK
Market cap
1.56B SEK
Turnover
403.17K SEK
Volume
12K
Financial calendar
Interim report
29.08.2024
Interim report
14.11.2024
Annual report
20.02.2025
Interim report
20.05.2025
General meeting
22.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Peter Unge | 7.7 % | 7.7 % |
Kjell Andersson | 7.3 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Stabilization notice
Number of shares and votes in Cinclus Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio